Dec. 15, 2019

-A +A

House Status: Adjourned until Monday, January 14, 2019 at 02:00 p.m.
Senate Status: Adjourned until Monday, January 14, 2019 at 02:00 p.m.

Minutes for HB2107 - Committee on Health and Human Services

Inclusion of biological products in the pharmacy act of the state of Kansas.

Chairperson Hawkins opened the hearing for proponents on HB2107.

Eileen Ma, Office of Revisor of Statutes, presented the bill brief on HB2107.

Proponents:

Greg Hoke, Director, Governmental Affairs, Biotechnology Innovation Organization (Attachment 1)

Thomas Felix, MD, Medical Director, R&D Policy, AMGEN (Attachment 2)

Mark Box, MD, Midwest Rheumatologist Society (Attachment 3)

Drue Duncan, Director, Governmental Relations, Pfizer (Attachment 4)

Philip Schneider, Professor, Associate Dean, University of Arizona College of Pharmacy (Attachment 5)

Staci Penner, Patient Advocate, Arthritis Foundation (Attachment 6)

Larrie Ann Brown, on behalf of Michael Harrold, Express Scripts (Attachment 7)

Eric Stafford, Vice President, Government Affairs, Kansas Chamber (Attachment 8)

Written proponents:

Alliance of Specialty Medicine (Attachment 9)

Kathleen Arntsen, President/CEO, Lupus and Allied Diseases Association, Inc. (Attachment 10)

Hilary Gee, Kansas Governmental Relations Director, American Cancer Society Action Network (Attachment 11)

Timothy Shaver, M.D., F.A.C.P., Arthritis and Rheumatology Clinics of Kansas (Attachment 12)

Marcia Horn, President/CEO, International Cancer Advocacy Network (Attachment 13)

Michael Stevens, President, Coalition of State Rheumatology Organizations (Attachment 14)

Michele Guadalupe, MPH, State Director of Advocacy and Access (Attachment 15)

After a question and answer period, the Chairperson closed the proponent hearing on HB2107 was closed.

Bills & Laws